Popular Articles

Clinical Data, Inc. Expands FAMILION(R) Long QT Syndrome Test By Doubling The Number Of Genes
PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), a biotechnology company developing targeted therapeutics and genetic and pharmacogenomic tests to detect diseases and predict drug safety, tolerability and efficacy, announced at the Heart Rhythm Society meeting that it will double the number of genes in its FAMILION Long QT Syndrome (LQTS) Test. By detecting genetic mutations in individuals and their families, the FAMILION LQTS Test can help guide treatment to prevent possible sudden cardiac death. This newly enhanced LQTS Test follows the 3-gene expansion of the FAMILION Hypertrophic Cardiomyopathy (HCM) Test released earlier this year and demonstrates the Company"s leadership in genetic testing for inherited cardiac disorders.

BioPartners GmbH Withdraws Its Application For Biferonex (interferon Beta-1a)
The European Medicines Agency has been formally notified by BioPartners GmbH of its decision to withdraw its application for Biferonex (interferon beta-1a), 6 million-international-unit solution for injection, prefilled syringes for subcutaneous administration.
News of the day
Parkinson's Disease Society Joins Forces With Healthy Interactions To Launch New Education Programme
As part of a Europe-wide drive to improve access to information and education for people with Parkinson"s Disease, the Parkinson"s Disease Society (PDS) is launching a new education initiative with American company, Healthy Interactions.
Public Health

Novel Clinical Practice Guideline Manual Released By ENT Society

The world"s largest ear, nose, and throat professional medical association, the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS), has released a manual detailing best practices for the creation of new clinical practice guidelines. The manual is published as a supplement to the June issue of Otolaryngology - Head and Neck Surgery. Clinical practice guidelines are created to help direct decisions and criteria regarding diagnosis, management, and treatment in medical practice. They seek to identify, summarize, and evaluate the best evidence and most current data about prevention, diagnosis, prognosis, therapy (medication/procedures), risk vs. benefit profile, and cost-effectiveness. "Clinical practice guidelines translate best evidence into best practice. A well-crafted guideline promotes quality by reducing healthcare variations, improving diagnostic accuracy, promoting effective therapy, and discouraging ineffective - or potentially harmful - interventions," said Richard M. Rosenfeld, MD, MPH, co-author of the guideline. "Despite a plethora of published guidelines, methodology is often poorly defined and varies greatly within and among organizations." According to the authors, published guidelines are often poorly suited to assess performance or influence care, because recommendations do not translate into measurable actions or activities. Moreover, the development process is generally inefficient and highly complex, requiring, on average, about two to three years per guideline. Using the process outlined in the new manual, the AAO-HNS was able to publish five multidisciplinary guidelines in five years, all within 12 months from conception to completion. The goals of publishing the manual were, first, to provide clinicians with a straightforward explanation of guidelines, considering their increasing prominence as a quality metric. Secondly, the manual is intended to be a pragmatic re, accurately reflecting current practices, in order to sustain consistency across guideline development practices. Finally, the manual seeks to share the AAO-HNS" successful development process with the medical community at large, to encourage an exchange of ideas and to promote best practices. "Our goal was to create an approach to guideline development that is both practical and transparent. Guideline users increasingly recognize that understanding the evidence supporting a recommendation is vital, but that authoring teams must additionally weigh and document anticipated benefits, risks, harms, and costs," said Richard N. Shiffman, MD, MCIS, co-author of the manual. The manual breaks down the development process and gives in-depth instructions for guideline task force administrators. The steps include planning, literature review, assigning the writing, peer review, organizational board review, and publication. As clinical practice guidelines become more prominent as key metrics of quality healthcare, organizations must develop efficient production strategies that balance rigor and pragmatism. Equally important, clinicians must become savvy in understanding what guidelines are - and are not - and how they are best utilized to improve care. The information in this manual should help clinicians and organizations achieve these goals, and improve patient care. Jessica Mikulski American Academy of Otolaryngology -- Head and Neck Surgery


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):